Linear-accelerator-based stereotactic irradiation for metastatic brain tumors

Takemoto Mitsuhiro, Kuniaki Katsui, Yoshida Atsushi, Himei Kengo, Kuroda Masahiro, Susumu Kanazawa, Sugita Katsuhiko, Kobayashi Mitsuru, Nakagawa Minoru, Fujimoto Shunichiro, Hiraki Yoshio

Research output: Contribution to journalArticlepeer-review


To assess the safety and availability of stereotactic radiotherapy (SRT) for metastatic brain tumors, we reviewed 54 consecutive cases with a total of 118 brain metastases treated with linear-accelerator-based stereotactic irradiation (STI). Nineteen patients with a total of 27 brain tumors that were larger than 3 cm or close to critical normal tissues were treated with SRT. The marginal dose of SRT was 15-21 Gy (median 21 Gy) in 3 fractions for 3 days. The median marginal dose of stereotactic radiosurgery (SRS) was 20 Gy. Effective rates of imaging studies were 72.7% and 94.4%, and those of clinical symptoms were 46.7 % and 55.6% for SRT and SRS, respectively. One-year and two-year survival rates of SRT were 40.9% and 17.6%, respectively, and the median follow-up period was 6.4 months. The one-year survival rate of SRS was 32.7 %, with a median follow-up of 4.6 months. Fourteen cases (7 cases each) had recurrent tumors at STI sites. Early complications were observed in one case of SRT and 8 cases of SRS, and late complications occurred in 3 cases of SRS. There were no significant differences among effective rates, survival rates, median follow-up times, recurrence rates, and complications between SRT and SRS. We concluded that SRT is a safe, effective therapy for large or eloquent area metastases.

Original languageEnglish
Pages (from-to)237-243
Number of pages7
JournalNippon Acta Radiologica
Issue number5
Publication statusPublished - May 25 2003


  • Brain metastasis
  • Stereotactic irradiation
  • Stereotactic radiosurgery
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology


Dive into the research topics of 'Linear-accelerator-based stereotactic irradiation for metastatic brain tumors'. Together they form a unique fingerprint.

Cite this